Elutia specializes in the development and marketing of biologic products aimed at enhancing compatibility between medical devices and the individuals requiring them. Its proprietary drug-eluting biologic technology combines natural biologic material with extended antibiotic release, tailored for device implantation and soft tissue reconstruction. The company's product line includes CanGaroo for implantable electronic devices and SimpliDerm for soft-tissue reconstruction, offering durable and user-friendly constructs that promote wound healing and ensure implant stability.